메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Suleimen Zhumatayev (Department of Pediatric Hematology and Oncology, Göztepe Medical Park Training and Education Hospital, Istanbul, Turkey) Koray Yalcin (Department of Pediatric Hematology and Oncology, Göztepe Medical Park Training and Education Hospital, Istanbul, Turkey) Safiye Suna Celen (Department of Pediatric Hematology and Oncology, Göztepe Medical Park Training and Education Hospital, Istanbul, Turkey) Vedat Uygun (Department of Pediatric Hematology and Oncology, Antalya Medical Park Training and Education Hospital, Antalya, Turkey) Gulsun Karasu (Department of Pediatric Hematology and Oncology, Göztepe Medical Park Training and Education Hospital, Istanbul, Turkey) Mehmet Akif Yesilipek (Department of Pediatric Hematology and Oncology, Göztepe Medical Park Training and Education Hospital, Istanbul, Turkey)
저널정보
대한소아혈액종양학회 Clinical Pediatric Hematology-Oncology Clinical Pediatric Hematology-Oncology 제31권 제1호
발행연도
2024.4
수록면
10 - 13 (4page)
DOI
10.15264/cpho.2024.31.1.10

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children, with a particularly poor prognosis in infants under one year of age. Hematopoietic stem cell transplantation (HSCT) is an effective therapy for relapsed or refractory ALL; however, relapse after HSCT remains a significant challenge. Many children cannot undergo HSCT because of serious adverse events from previous treatment. In this case report, we present the case of an infant with relapsed/refractory ALL who received blinatumomab as salvage therapy after a second haploidentical HSCT and remained in remission for 15 months without subsequent HSCT. The patient was a 4-month-old male diagnosed with high-risk infant B-cell ALL with KMT2A/AFF1. He received induction chemotherapy according to the INTERFANT-06 protocol and achieved complete remission. He underwent 10/10 matched-sibling bone marrow transplantation but experienced an isolated marrow relapse 2 months post-transplant and then received a second haploidentical HSCT. He was treated with one cycle of blinatumomab after the relapse that occurred after the second HSCT. Due to toxicity, the patient did not receive a third transplant but was followed up after blinatumomab. And the patient remained in complete remission for 15 months after the blinatumomab therapy. Blinatumomab has been known as a bridging therapy. We suggest that blinatumomab could be a promising curative therapy option for patients who cannot receive further HSCT.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0